Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Lepu Medical Acquires Betagrin Rights from Bio-Thera in RMB 450 Million Cardiovascular Deal

Fineline Cube Apr 15, 2026
Company Deals

Eli Lilly to Acquire CrossBridge Bio for Up to $300 Million to Bolster ADC Pipeline with Novel TROP2-Targeting Candidate

Fineline Cube Apr 15, 2026
Company Deals

WinHealth Pharma Licenses World’s First Oral Arsenic Trioxide Arsenol for Mainland China APL Treatment

Fineline Cube Apr 14, 2026
Company Deals

Thermo Fisher’s PPD Secures 270M-Patient HealthVerity Dataset for AI-Driven Clinical Trial Optimization

Fineline Cube Apr 14, 2026
Company Deals

China Resources and Roche Partner on Trastuzumab Emtansine Commercialization to Expand Breast Cancer ADC Access

Fineline Cube Apr 14, 2026
Policy / Regulatory

FDA Issues Draft Guidance for Genome Editing Therapy Safety Assessment Using Next-Generation Sequencing

Fineline Cube Apr 15, 2026
Company Drug

Huadong Medicine’s Semaglutide Biosimilar HDM1702 Enters NMPA Review for Weight Management Indication

Fineline Cube Apr 15, 2026
Company Drug

Laekna Therapeutics Reports Breakthrough Phase III Results for LAE002 AKT Inhibitor in HR+/HER2- Breast Cancer

Fineline Cube Apr 15, 2026
Company Drug

Lee’s Pharmaceutical Commences Phase I Clinical Trial for AI-Discovered HCC Drug AU409

Fineline Cube Aug 2, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a leading biopharmaceutical company based in China, has announced...

Company Medical Device

Roche’s Alzheimer’s Disease Diagnostic Kits Gain Approval in Hainan, Set for Use in Shanghai Ruijin Hospital

Fineline Cube Aug 2, 2024

Swiss pharmaceutical and diagnostics giant Roche (SWX: ROG) has received approval from the Hainan Medical...

Company Deals

Mabwell Bioscience Secures Rights to Risen Pharmaceutical’s OA Treatment in Greater China

Fineline Cube Aug 2, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a leading biopharmaceutical company in China, has entered...

Company Drug

Suzhou Zelgen’s Jacktinib Tablets Achieve Positive Results in Phase II IPF Clinical Trial

Fineline Cube Aug 2, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...

Company Deals

ImmuneOnco Biopharmaceuticals Strikes Licensing Deal with Instil Bio for Global Rights to Dual-Targeted Antibodies

Fineline Cube Aug 2, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has entered into a definitive licensing agreement with...

Company Drug

Sino Biopharmaceutical’s Benmelstobart Files for New Indication in China for Advanced RCC Treatment

Fineline Cube Aug 2, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced that...

Company Medical Device

AbbVie’s Allergan Aesthetics Wins NMPA Approval for Juvéderm Dermal Filler in China

Fineline Cube Aug 2, 2024

Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has secured marketing approval from China’s National...

Company Drug

Innovent Biologics’ Mazdutide NDA for Type 2 Diabetes Accepted for Review in China

Fineline Cube Aug 2, 2024

Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company in China, has announced that the...

Company Drug

GSK’s Jemperli Receives EC Approval for Endometrial Cancer Treatment in Combination Therapy

Fineline Cube Aug 2, 2024

GSK plc (NYSE: GSK), a leading UK pharmaceutical company, has announced that the European Commission...

Company Deals

Fapon Biotech Expands Global Footprint with New IVD Manufacturing Facility in Indonesia

Fineline Cube Aug 2, 2024

China-based in vitro diagnostic (IVD) company Fapon Biotech has announced a strategic investment with the...

Company Deals

Kyowa Kirin Revamps APAC Strategy, Exits China and Shifts R&D Focus

Fineline Cube Aug 2, 2024

Japan’s pharmaceutical group Kyowa Kirin Co., Ltd (TYO: 4151) has announced a significant restructuring of...

Company Deals

Otsuka Pharmaceutical to Acquire US Biotech Jnana Therapeutics in $1.1 Billion Deal

Fineline Cube Aug 2, 2024

Otsuka Pharmaceutical Co., Ltd, a leading Japanese pharmaceutical company, has announced the signing of a...

Policy / Regulatory

US Lawmakers Probe Clinical Trials at Hospitals Linked to Chinese Military, Potential Impact on Pharma Industry

Fineline Cube Aug 1, 2024

Reports from BioCentury and Endpoints News, based on anonymous insider sources, suggest that US lawmakers...

Policy / Regulatory

China’s Health Authorities Set Standards for Key Central Township Health Centers

Fineline Cube Aug 1, 2024

The National Health Commission (NHC), National Disease Control and Prevention Administration, and National Administration of...

Policy / Regulatory

China’s State Council Unveils Five-Year Plan to Enhance Urbanization and Address “Three Rural Issues”

Fineline Cube Aug 1, 2024

The State Council of China has released a “Five Year Action Plan for Deepening the...

Policy / Regulatory

Shanghai Aims to Become Capital Market Hub for High-Quality Science and Innovation Companies

Fineline Cube Aug 1, 2024

The Shanghai municipal government has unveiled a comprehensive set of measures designed to enhance the...

Company Deals Legal / IP

Sirnaomics Ltd Forms JV with Gore Range Capital to Pioneer Medical Aesthetics Innovations

Fineline Cube Aug 1, 2024

Sirnaomics Ltd (HKG: 2257), a biopharmaceutical company specializing in RNAi therapeutics, has announced the formation...

Company Medical Device

MicroPort Scientific’s Bioabsorbable Stent System Gains NMPA Nod for Ischemic Heart Disease Treatment

Fineline Cube Aug 1, 2024

Shanghai-based medical device conglomerate MicroPort Scientific Corp. (HKG: 0853) has announced that it has received...

Company

HutchMed Reports 2024 H1 Financials with Mixed Results Amid Strategic Focus on R&D and Commercial Efficiency

Fineline Cube Aug 1, 2024

China-based HutchMed (NASDAQ: HCM) has released its financial report for the first half of 2024,...

Company Drug

Tonghua Dongbao Pharmaceuticals Launches Phase III Clinical Trial for Semaglutide Biosimilar in China

Fineline Cube Aug 1, 2024

Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has announced the commencement of a...

Posts pagination

1 … 305 306 307 … 651

Recent updates

  • Huadong Medicine’s Semaglutide Biosimilar HDM1702 Enters NMPA Review for Weight Management Indication
  • Lepu Medical Acquires Betagrin Rights from Bio-Thera in RMB 450 Million Cardiovascular Deal
  • Eli Lilly to Acquire CrossBridge Bio for Up to $300 Million to Bolster ADC Pipeline with Novel TROP2-Targeting Candidate
  • Laekna Therapeutics Reports Breakthrough Phase III Results for LAE002 AKT Inhibitor in HR+/HER2- Breast Cancer
  • Johnson & Johnson Reports Strong Q1 2026 Sales Growth Despite Net Earnings Decline; Raises Full-Year Guidance
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Huadong Medicine’s Semaglutide Biosimilar HDM1702 Enters NMPA Review for Weight Management Indication

Company Deals

Lepu Medical Acquires Betagrin Rights from Bio-Thera in RMB 450 Million Cardiovascular Deal

Company Deals

Eli Lilly to Acquire CrossBridge Bio for Up to $300 Million to Bolster ADC Pipeline with Novel TROP2-Targeting Candidate

Company Drug

Laekna Therapeutics Reports Breakthrough Phase III Results for LAE002 AKT Inhibitor in HR+/HER2- Breast Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.